imatinib mesylate has been researched along with Proteinuria in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Himuro, N; Ito, K; Masutani, K; Miyake, K; Morita, N; Nakayama, T; Nawata, A; Ozaki, T; Sasaki, H; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T; Yokota, S | 1 |
| Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y | 1 |
| Akizawa, T; Iyoda, M; Kawaguchi, M; Shibata, T; Yamaoka, T | 1 |
| Akizawa, T; Iyoda, M; Kuno, Y; Matsumoto, K; Shibata, T; Shindo-Hirai, Y; Wada, Y | 1 |
| Harada, M; Hirakata, H; Igawa, T; Masutani, K; Miyake, K; Nakashima, H; Niiro, H; Sadanaga, A; Shimizu, S; Sugiyama, N | 1 |
| Abbate, M; Corna, D; Remuzzi, G; Rottoli, D; Zanchi, C; Zoja, C | 1 |
1 trial(s) available for imatinib mesylate and Proteinuria
| Article | Year |
|---|---|
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Dasatinib; Diarrhea; DNA Copy Number Variations; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Stromal Tumors; Genotype; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neutropenia; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Proteinuria; Sunitinib | 2020 |
5 other study(ies) available for imatinib mesylate and Proteinuria
| Article | Year |
|---|---|
Focal segmental glomerulosclerosis and concurrent glomerular microangiopathy after long-term imatinib administration.
Topics: Aged; Endothelial Cells; Female; Glomerulosclerosis, Focal Segmental; Humans; Imatinib Mesylate; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proteinuria | 2022 |
Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis.
Topics: Animals; Basement Membrane; Benzamides; Creatinine; Glomerulonephritis; Imatinib Mesylate; Kidney Glomerulus; Macrophages; Piperazines; Protective Agents; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Treatment Outcome; Urea | 2009 |
Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Benzamides; Collagen Type I; Creatinine; Disease Progression; Female; Fluorescent Antibody Technique; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Proteinuria; Pyrimidines; Rats; Rats, Inbred WKY; Real-Time Polymerase Chain Reaction; Renal Insufficiency, Chronic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transforming Growth Factor beta | 2013 |
Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
Topics: Animals; Antineoplastic Agents; Autoantibodies; Benzamides; Blood Urea Nitrogen; CD4-Positive T-Lymphocytes; Creatinine; DNA; Female; Glomerulonephritis; Imatinib Mesylate; Immunoglobulin G; Interferon-gamma; Lupus Nephritis; Lymphatic Diseases; Mice; Mice, Inbred MRL lpr; Piperazines; Platelet-Derived Growth Factor; Proteinuria; Pyrimidines; Salivary Glands; Severity of Illness Index; Spleen; Splenomegaly; Survival Analysis | 2005 |
Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease.
Topics: Actins; Animals; Antigens, Differentiation; Benzamides; Female; Fibroblasts; Imatinib Mesylate; Kidney; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Muscle, Smooth; Piperazines; Protein Kinase Inhibitors; Proteinuria; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2006 |